navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2022-04-06 12:58:18 +00:00
parent cb57a03d6b
commit fa6e037409
3 changed files with 683 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

211
archive-covid-19/06 April, 2022.html Normal file
View File

@ -0,0 +1,211 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>06 April, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Single-Friendly Work Cultures and Work-Life Balance During the COVID-19 Pandemic: A Study Across Four European Countries</strong> -
<div>
This study aimed to explore the differences in perceptions of a single-friendly work culture (SFWC) and work-life balance (WLB) among single employees in four European countries: Croatia, Denmark, Italy, and Portugal. It also aimed to consider single employees’ experiences unique to the events of COVID-19. A total of 722 single, childless employees, of which 191 from Italy, 182 Portugal, 180 Croatia, and 160 Denmark, completed an online set of self-report instruments. The results were mostly in line with the expectation that singlehood acceptance and WLB is higher, and work cultures are more single-friendly in more egalitarian countries: from Denmark, to Croatia, Portugal, and Italy. In all countries, social acceptance of singlehood variables was weakly to moderately positively correlated to WLB, while these variables’ correlations with the SFWC factors were mostly non-significant for Denmark. The participants’ open-ended responses indicated that they felt employers and colleagues expected them to pick up extra shifts or be more flexible in planning, e.g. vacation schedules, during the pandemic and in general. Another prominent theme across countries was financial differentiation amongst employees according to relationship status. These results might heighten awareness of nations and organizations to the need to consider singles’ issues in forming policies.
</div>
<div class="article-link article- html-link">
🖺 Full Text HTML: <a href="https://osf.io/utnzb/" target="_blank">Single-Friendly Work Cultures and Work-Life Balance During the COVID-19 Pandemic: A Study Across Four European Countries</a>
</div></li>
<li><strong>Transparency of COVID-19-Related Research in Dental Journals</strong> -
<div>
We aimed to assess the adherence to transparency practices (data availability, code availability, statements of protocol registration and conflicts of interest and funding disclosures) and FAIRness (Findable, Accessible, Interoperable, and Reusable) of shared data from open access COVID-19-related articles published in dental journals available from the Europe PubMed Central (PMC) database.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/rqc2b/" target="_blank">Transparency of COVID-19-Related Research in Dental Journals</a>
</div></li>
<li><strong>Automated method to extract and purify RNA from wastewater enables more sensitive detection of SARS-CoV-2 markers in community sewersheds</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Wastewater based epidemiology (WBE) has emerged as a strategy to identify, locate, and manage outbreaks of COVID19, and thereby possibly prevent surges in cases, which overwhelm local to global health care networks. The WBE process is based on assaying municipal wastewater for molecular markers of the SARS-CoV-2 virus. The standard process for sampling municipal wastewater is both time-consuming and requires the handling of large quantities of wastewater, which negatively affect throughput and timely reporting, and can increase safety risks. We report on a method to assay multiple sub-samples of a bulk wastewater sample. We document the effectiveness of this new approach by way of comparison of technologies for automating RNA purification from wastewater samples. We compared processes using the Perkin-Elmer Chemagic(TM) 360 to a PEG/NaCl/Qiagen protocol that is used for detection of N1 and N2 SARS-CoV-2 markers by the majority of 19 pandemic wastewater testing labs in the State of Michigan. Specifically, we found that the Chemagic(TM) 360 lowered handling time, decreased the amount of wastewater required by 10-fold, increased the amount of RNA isolated per microliter of final elution product by approximately five-fold, and had no deleterious effect on subsequent ddPCR analysis. Moreover, for detection of markers on the borderline of detectability, we found that use of the Chemagi(TM) 360 enabled the detection of viral markers in a significant number of samples for which the result with the PEG/NaCl/Qiagen method was below the level of detectability. This improvement in detectability of the viral markers might be particularly important for early warning to public health authorities at the beginning of an outbreak.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.03.22273370v1" target="_blank">Automated method to extract and purify RNA from wastewater enables more sensitive detection of SARS-CoV-2 markers in community sewersheds</a>
</div></li>
<li><strong>Nonutility of procalcitonin for diagnosing bacterial pneumonia in COVID-19</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection. To do so, we identified 185 patients with severe COVID-19 who underwent lower respiratory culture; 85 had superinfection. Receiver operating characteristic curve analysis showed that procalcitonin at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). We conclude that static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.29.22272960v1" target="_blank">Nonutility of procalcitonin for diagnosing bacterial pneumonia in COVID-19</a>
</div></li>
<li><strong>Modeling behavior change and underreporting in the early phase of COVID-19 pandemic in Metro Manila, Philippines</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
When the Philippine government eased the community quarantine restrictions on June 2020, the healthcare system was overwhelmed by the surge in coronavirus disease 2019 (COVID-19) cases. In this study, we developed an SEIQR model considering behavior change and unreported cases to examine their impact on the COVID-19 case reports in Metro Manila during the early phase of the pandemic. We found that if behavior was changed one to four weeks earlier, then the cumulative number of cases can be reduced by up to 74% and the peak delayed by up to four weeks. Moreover, a two- or threefold increase in the reporting ratio can decrease the cumulative number of cases by 29% or 47%, respectively, at the end of September 2020. Results of our finding are expected to guide healthcare professionals to mitigate disease spread and minimize socioeconomic burden of strict lockdown policies during the start of an epidemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.29.22273148v1" target="_blank">Modeling behavior change and underreporting in the early phase of COVID-19 pandemic in Metro Manila, Philippines</a>
</div></li>
<li><strong>Combination of Baricitinib plus Remdesivir and Dexamethasone improves time to recovery and mortality among hospitalized patients with severe COVID-19 infection</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: There seems to be a gap in the therapeutic options for severe Covid-19 pneumonia. Though the beneficial effect of combination treatment with baricitnib and remdesivir in accelerating clinical status improvement is described, the impact of the triple therapy with baricitinib + remdesivir/dexamethasone is not known. Methods: A retrospective observational study comparing the effect of baricitinib plus standard treatment (remdesivir and dexamethasone) with standard therapy in patients requiring &gt; 5 L/min O2 was conducted. The primary outcome was to compared time to recovery in both groups, and the secondary outcomes was to determine mortality rate at discharge. Results: Of 457 patients hospitalized during the study period, 51 patients received standard treatment while 88 patients received baricitinib plus standard treatment. In baricitinib group, the rate ratio of recovery was 1.28 (95%CI 0.84-1.94, p=0.24) with a reduction in median time to recovery of 3 days compared to standard treatment group. Subgroup analysis based on Ordinal Scale showed reduction in median time to recovery by 4 and 2 days with rate ratio of recovery of 2.95 (1.03-8.42, p =0.04) and 1.80 (1.09-2.98, p=0.02) in Ordinal Scale 5 and 6 respectively. No benefit was found in the Ordinal Scale 7 subgroup. An overall decrease in rate (15.9% vs 31.4% p=0.03) a likelihood (OR 0.41, 95%CI 0.18-0.94, p=0.03) of mortality was observed in the baricitinib group. Bacteremia and thrombosis were noted in the Baricitinib group, but comparable with the Standard of care group. Conclusion: Baricitinib with standard therapy reduced time to recovery and offer mortality benefit in patients with severe COVID-19 pneumonia.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22273425v1" target="_blank">Combination of Baricitinib plus Remdesivir and Dexamethasone improves time to recovery and mortality among hospitalized patients with severe COVID-19 infection</a>
</div></li>
<li><strong>Linking private health sector to public COVID-19 response in Kisumu, Kenya: Lessons Learnt</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: COVID-19 is overwhelming health systems universally. Increased capacity to combat the epidemic is important, while continuing regular healthcare services. This paper describes an innovative Public Private Partnership (PPP) against COVID-19 that from the onset of the epidemic was established in Kisumu County, Western Kenya. Methods: An explanatory research design was used. Qualitative in-depth interviews (n=49) were conducted with purposively selected participants including patients, health workers, and policy makers. Thematic analysis was undertaken on interview transcripts and triangulation was performed. Results: The PPP hinged through the provision of central diagnostic COVID-19 services through a parastatal institute (KEMRI). Complementary tasks were divided between Kisumu Department of Health and public and private healthcare providers, supported by an NGO. Facilitators to this PPP included implementation of MoH Guidelines, digitalization of data, strengthening of counseling services and free access to COVID-19 testing services in private facilities. Barriers included, data accessibility, sub optimal financial management. Conclusion: Coordinated PPP can rapidly enhance capacity and quality of COVID-19 epidemic management in African settings. Our PPP model appears scalable, as proven by current developments. Lessons learnt from this initial PPP in Kisumu County will be beneficial to expanding epidemic preparedness to other Counties in Kenya and beyond. Key words : COVID-19, Private-Public Partnership, Kenya, Qualitative Research
</p>
</div>
<div class="article-link article- html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.29.22271489v1" target="_blank">Linking private health sector to public COVID-19 response in Kisumu, Kenya: Lessons Learnt</a>
</div></li>
<li><strong>Determinants of mortality among COVID-19 patients with diabetes mellitus in Addis Ababa, Ethiopia, 2022: An unmatched case-control study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Introduction: COVID-19 remains one of the leading causes of death seeking global public health attention. Diabetes mellitus is associated with severity and lethal outcomes up to death independent of other comorbidities. Nevertheless, information regarding the determinant factors that contributed to the increased mortality among diabetic COVID-19 patients is limited. Thus, this study aimed at identifying the determinants of mortality among COVID-19 infected diabetic patients. Methods: An unmatched case-control study was conducted on 340 randomly selected patients by reviewing patient records. Data were collected using a structured extraction checklist, entered into Epi data V-4.4.2.2, and analyzed using SPSS V-25. Then, binary logistic regression was used for bivariate and multivariable analysis. Finally, an adjusted odds ratio with 95% CI and a p-value of less than 0.05 was used to determine the strength of association and the presence of a statistical significance consecutively. Results: The study was conducted on 340 COVID-19 patients (114 case and 226 controls). Patient age (AOR=4.90; 95% CI: 2.13, 11.50), severity of COVID-19 disease (AOR=4.95; 95% CI: 2.20, 11.30), obesity (AOR=7.78; 95% CI: 4.05, 14.90), hypertension (AOR=5.01; 95% CI: 2.40, 10.60), anemia at presentation (AOR=2.93; 95% CI: 1.29, 6.65), and AKI after hospital admission (AOR=2.80; 95% CI: 1.39, 5.64) had statistically significant association with increased mortality of diabetic patients with COVID-19 infection. Conversely, presence of RVI co-infection was found to be protective against mortality (AOR=0.35; 95% CI: 0.13, 0.90). Conclusion: Patient age (&lt;65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on admission was independently associated with increased mortality of diabetic COVID-19 patients. Contrariwise, the presence of RVI co-infection was found to be protective against patient death. Consequently, COVID-19 patients with diabetes demand untiring efforts, and focused management of the identified factors will substantially worth the survival of diabetic patients infected with COVID-19.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22273344v1" target="_blank">Determinants of mortality among COVID-19 patients with diabetes mellitus in Addis Ababa, Ethiopia, 2022: An unmatched case-control study</a>
</div></li>
<li><strong>Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Despite early clinical success, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here, we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) using high-resolution, single-cell multiomics. We confirmed that iLD-IL-2 selectively expands thymic-derived FOXP3+HELIOS+ Tregs and CD56br NK cells, and provide new evidence for an IL-2-induced reduction of highly differentiated IL-21-producing CD4+ T cells. We also discovered that iLD-IL-2 induces an anti-inflammatory gene expression signature, which was detected in all T and NK cell subsets even one month after treatment. The same signature was present in COVID-19 patients, but in the opposite direction. These findings indicate that the sustained Treg and CD56br NK cell increases induced by our 4-week iLD-IL2 treatment create a long-lasting and global anti-inflammatory environment, warranting further investigations of the potential clinical benefits of iLD-IL-2 in immunotherapy, including the possibility of reversing the pro-inflammatory environment in COVID-19 patients.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.05.22273167v1" target="_blank">Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients</a>
</div></li>
<li><strong>Effectiveness of a nation-wide COVID-19 vaccination program in Mexico</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
BACKGROUND: Vaccination has been effective in ameliorating the impact of COVID-19. However, estimation of vaccine effectiveness (VE) is still unavailable for some widely used vaccines and underrepresented groups. Here, we report on the effectiveness of a nation-wide COVID-19 vaccination program in Mexico. METHODS: We used a test-negative design within a national COVID-19 surveillance system to assess VE of the BNT162b2, mRNA-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1 and CoronaVac vaccines, against SARS-CoV-2 infection, COVID-19 related hospitalization and death for adults ≥18 years in Mexico. VE was estimated using Cox proportional hazard models considering time-varying vaccination status in partial and fully vaccinated individuals compared to unvaccinated adults, adjusted by age, sex, comorbidities and municipality. We also estimated VE for adults ≥60 years, for cases with diabetes and comparing periods with predominance of variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated compared to 4,792,338 unvaccinated adults between December 24th, 2020, and September 27th, 2021. VE against SARS-CoV-2 infection was highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95%CI 90.3-92.4) and Ad26.COV2.S (82.2%, 95%CI 81.4-82.9), whereas for COVID-19 related hospitalization were BNT162b2 (84.3%, 95%CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95%CI 79.5-83.1) and for mortality BNT162b2 (89.8%, 95%CI 89.2-90.2) and mRNA-12732 (93.5%, 95%CI 86.0-97.0). VE for all evaluated vaccines was reduced for adults ≥60 years, people with diabetes, and in periods of Delta variant predominance. CONCLUSIONS: All evaluated vaccines were effective against SARS-CoV-2 infection and COVID-19 related hospitalization and death. Mass vaccination campaigns with multiple vaccine products are feasible and effective to maximize vaccination coverage.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22273330v1" target="_blank">Effectiveness of a nation-wide COVID-19 vaccination program in Mexico</a>
</div></li>
<li><strong>A prospective cohort study of presenteeism and increased risk of unemployment among Japanese workers</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: We examined the association between presenteeism and risk of job resignations and unemployment among Japanese workers during the COVID-19 pandemic. Methods: A prospective study of 27,036 Internet monitors was conducted, starting in December 2020, with 18,560 (68.7%) participating in the follow-up by December 2021. The Work Functioning Impairment Scale (WFun) was used to measure the degree of work function impairment. Results: The group with the highest WFun scores had higher odds ratios (ORs) for both retirement and unemployment for health reasons than the group with the lowest WFun scores. ORs were 2.97 (95%CI: 2.46-3.59, p&lt;0. 001) and 1.80 (95%CI: 1.64-1.98, p&lt;0.001), respectively. Conclusions: Workers with work functioning impairment were at increased risk of resignation or unemployment. Management strategies for workers with work functioning impairment are needed to reduce their disadvantages in employment.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22273011v1" target="_blank">A prospective cohort study of presenteeism and increased risk of unemployment among Japanese workers</a>
</div></li>
<li><strong>Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: In January 2022, United States guidelines shifted to recommend isolation for 5 days from symptom onset, followed by 5 days of mask wearing. However, viral dynamics and variant and vaccination impact on culture conversion are largely unknown. Methods: We conducted a longitudinal study on a university campus, collecting daily anterior nasal swabs for at least 10 days for RT-PCR and culture, with antigen rapid diagnostic testing (RDT) on a subset. We compared culture positivity beyond day 5, time to culture conversion, and cycle threshold trend when calculated from diagnostic test, from symptom onset, by SARS-CoV-2 variant, and by vaccination status. We evaluated sensitivity and specificity of RDT on days 4-6 compared to culture. Results: Among 92 SARS-CoV-2 RT-PCR positive participants, all completed the initial vaccine series,17 (18.5%)were infected with Delta and 75 (81.5%) with Omicron. Seventeen percent of participants had positive cultures beyond day 5 from symptom onset with the latest on day 12. There was no difference in time to culture conversion by variant or vaccination status. For the 14 sub-study participants, sensitivity and specificity of RDT were 100% and 86% respectively. Conclusions: The majority of our Delta-and Omicron- infected cohort culture-converted by day 6, with no further impact of booster vaccination on sterilization or cycle threshold decay. We found that rapid antigen testing may provide reassurance of lack of infectiousness, though masking for a full 10 days is necessary to prevent transmission from the 17% of individuals who remain culture positive after isolation.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22273429v1" target="_blank">Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study</a>
</div></li>
<li><strong>Workplace ventilation improvement to address coronavirus disease 2019 cluster occurrence in a manufacturing factory</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A coronavirus disease 2019 (COVID-19) cluster emerged in a manufacturing factory in early August 2021. In November 2021, a ventilation survey using tracer gas was performed to reproduce the situation at the time of cluster emergence and verify that ventilation in the office increased the risk of aerosol transmission; verify the effectiveness of measures implemented immediately in August; and verify the effectiveness of additional measures when previously enforced measures proved inadequate. At the time of cluster emergence, the average ventilation rate was 0.73 times/h, less than the 2 times/h recommended by the Ministry of Health, Labour, and Welfare; as such, the factory9s situation was deemed to have increased the risk of aerosol transmission. Due to the measures already taken at the time of the survey, the ventilation rate increased to 3.41 times/h on average. It was confirmed that ventilation rate increased to 8.33 times/h on average, when additional measures were taken. To prevent the re-emergence of COVID-19 clusters, it is necessary to continue the measures that have already been implemented. Additionally, introduction of real-time monitoring that visualizes CO2 concentrations, which can be used to determine the timing of ventilation and limit the number of people entering the room, is recommended.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.04.22271935v1" target="_blank">Workplace ventilation improvement to address coronavirus disease 2019 cluster occurrence in a manufacturing factory</a>
</div></li>
<li><strong>Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: A cohort analysis of 2.7M people.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: To examine if SARS-CoV-2 infections vary by vaccination status, if an individual had previously tested positive and by neighbourhood socioeconomic deprivation across the Delta and Omicron epidemic waves of SARS- CoV-2. Design: Cohort study using electronic health records Setting: Cheshire and Merseyside, England (3rd June 2021 to 1st March 2022) Participants: 2.7M residents Main Outcome measure: Registered positive test for SARS-CoV-2 Results: Social inequalities in registered positive tests were dynamic during the study. Originally higher SARS-CoV-2 rates in the most socioeconomically deprived neighbourhoods changed to being higher in the least deprived neighbourhoods from the 1st September 2021. While the introduction of Omicron initially reset inequalities, they continued to be dynamic and inconsistent. Individuals who were fully vaccinated (two doses) were associated with fewer registered positive tests (e.g., between 1st September and 27th November 2021: (i) individuals engaged in testing - Hazards Ratio (HR) = 0.48, 95% Confidence Intervals (CIs) = 0.47-0.50; (ii) individuals engaged with healthcare - HR = 0.34, 95% CIs = 0.33-0.34). Individuals with a previous registered positive test were also less likely to have a registered positive test (e.g., between 1st September and 27th November 2021: (i) individuals engaged in testing - HR = 0.16, 95% CIs = 0.15-0.18; (ii) individuals engaged with healthcare - HR = 0.14, 95% CIs = 0.13-0.16). However, Omicron is disrupting these associations due to immune escape resulting in smaller effect sizes for both measures. Conclusions: Changing patterns of SARS-CoV-2 infections during the Delta and Omicron waves reveals a dynamic pandemic that continues to affect diverse communities in sometimes unexpected ways.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.04.05.22273169v1" target="_blank">Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: A cohort analysis of 2.7M people.</a>
</div></li>
<li><strong>Cannabis potential effects to prevent or attenuate SARS-COV2 contagion</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Medical cannabis has gained an exponential interest in recent years. Therapeutic targets have been broadened from specific applications over pain control, chemotherapy side effects, treatment-resistant epilepsies and multiple sclerosis, among others. Several in vitro and animal studies, along with few human controlled studies, suggest cannabinoids have a potential therapeutic role over medical conditions comporting inflammatory mechanisms. Given the tremendous world-wide impact of the COVID-19 pandemic, research efforts are converging towards the use of cannabinoids to attenuate severe or fatal forms of the disease. The present survey aims to explore possible correlations between cannabis use, either recreational or medical, over the presence of SARS-COV-2 contagion, along with the symptoms severity. 4026 surveys were collected via electronic form. Results suggest a relation between any type of cannabis use and a lower risk of SARS-COV-2 contagion (p=0,004; OR=0,689, IC95% 0,534-0,889). Despite several methodological limitations, the present survey steps up the urge to expand our understanding on cannabinoids potential use on human controlled studies, that can better arm us in the fight against the current COVID-19 pandemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.31.22273181v1" target="_blank">Cannabis potential effects to prevent or attenuate SARS-COV2 contagion</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09);   Biological: Inactivated COVID-19 vaccine (Vero cells)<br/><b>Sponsors</b>:  <br/>
National Vaccine and Serum Institute, China;   China National Biotec Group Company Limited;   Lanzhou Institute of Biological Products Co., Ltd;   Beijing Institute of Biological Products Co Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Randomized Controlled Clinical Trial to Evaluate The Efficacy and Safety of Healthtone as Prophylaxis for COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Dietary Supplement: Rhea® Health Tone<br/><b>Sponsor</b>:   Indonesia University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Aerobic Exercise in People With Post-COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Other: Conventional rehabilitation;   Other: Aerobic exercise<br/><b>Sponsor</b>:   Istituti Clinici Scientifici Maugeri SpA<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy, Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: SARS-CoV-2 protein subunit recombinant vaccine;   Biological: placebo<br/><b>Sponsors</b>:   PT Bio Farma;   Faculty of Medicine, Universitas Indonesia, Jakarta;   Faculty of Medicine, Diponegoro University, Semarang;   Faculty of Medicine, Universitas Andalas, Padang;   Faculty of Medicine, Universitas Hassanudin, Makassar<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Effectiveness and Safety of SCTV01E (a Recombinant Protein COVID-19 Vaccine) in Population Aged ≥12 Years</strong> - <b>Conditions</b>:   COVID-19;   SARS-CoV-2 Infection<br/><b>Interventions</b>:   Biological: SCTV01E;   Biological: CoronaVac;   Biological: Sinopharm inactivated COVID-19 vaccine;   Biological: other approved COVID-19 vaccines<br/><b>Sponsor</b>:   Sinocelltech Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years</strong> - <b>Conditions</b>:   COVID-19;   SARS-CoV-2 Infection<br/><b>Interventions</b>:   Biological: SCTV01C;   Biological: SCTV01E;   Biological: mRNA vaccine manufactured by Pfizer or Moderna;   Biological: Sinopharm inactivated COVID-19 vaccine<br/><b>Sponsor</b>:   Sinocelltech Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Treatment Cascade Optimization Study</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Behavioral: Navigation Services;   Behavioral: Brief Counseling;   Behavioral: Critical Dialogue;   Behavioral: Referral and Digital Brochure<br/><b>Sponsors</b>:   University of Illinois at Urbana-Champaign;   National Institute of Allergy and Infectious Diseases (NIAID);   Comprehensive Behavioral Health Center;   North Jersey Community Research Initiative;   University of Michigan<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: IBIO123;   Other: Placebo<br/><b>Sponsor</b>:   Immune Biosolutions Inc<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Compass Course: COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Behavioral: Compass Course<br/><b>Sponsor</b>:  <br/>
Allina Health System<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Improving COVID-19 Vaccine Uptake Among Black and Latino Youth</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Behavioral: Culturally-Tailored COVID-19 Vaccine Uptake Intervention;   Behavioral: Standard Care<br/><b>Sponsors</b>:   Nemours Children’s Health System;   National Institute of General Medical Sciences (NIGMS);   University of Delaware;   ChristianaCare<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase 1&amp;2 Study to Evaluate the Safety &amp; Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: IBIO123;   Other: Placebo<br/><b>Sponsor</b>:   Immune Biosolutions Inc<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Evaluation of Rapid RNA Test for Covid-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Diagnostic Test: rapid RT-LAMP test to detect SARS-COV-2 RNA<br/><b>Sponsors</b>:   University of Southampton;   West Hertfordshire Hospitals NHS Trust;   University of Oxford<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Evaluation of Rapid Antibody Test for Covid-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Diagnostic Test: Livzon Rapid Antibody Test for COVID-19<br/><b>Sponsors</b>:   University of Southampton;   West Hertfordshire Hospitals NHS Trust<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ApTOLL for the Treatment of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: ApTOLL;   Other: Saline<br/><b>Sponsors</b>:  <br/>
Macarena Hernández Jiménez;   Centro para el Desarrollo Tecnológico Industrial<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine</strong> - <b>Condition</b>:   COVID-19 Vaccines<br/><b>Interventions</b>:   Biological: UB-612;   Biological: BNT162b2 vaccine;   Biological: ChAdOx1-S vaccine;   Biological: Sinopharm BIBP<br/><b>Sponsors</b>:   Vaxxinity, Inc.;   Syneos Health<br/><b>Recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Herbal inhibitors of SARS-CoV-2 M(pro) effectively ameliorate acute lung injury in mice</strong> - Coronavirus disease 2019, a newly emerging serious infectious disease, has spread worldwide. To date, effective drugs against the disease are limited. Traditional Chinese medicine was commonly used treating COVID-19 patients in China. Here we tried to identify herbal effective lipid compounds from the lipid library of 92 heat-clearing and detoxication Chinese herbs. Through virtual screening, enzymatic activity and inhibition assays and surface plasmon resonance tests, we identified lipid…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Computational design and experimental characterisation of a stable human heparanase variant</strong> - Heparanase is the only human enzyme known to hydrolyse heparin sulfate and is involved in many important physiological processes. However, it is also unregulated in many disease states, such as cancer, diabetes and Covid-19. It is thus an important drug target, yet the heterologous production of heparanase is challenging and only possible in mammalian or insect expression systems, which limits the ability of many laboratories to study it. Here we describe the computational redesign of heparanase…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model</strong> - Ivermectin is widely used in both animals and humans as an FDA-approved parasiticide. Ivermectin has also been reported to have antiviral activity against several viruses including coronaviruses. There are reports that indicate ivermectin may have some role in diminishing the disease caused by SARS-CoV-2, but the evidence is inconclusive. The objective of this study was to determine if ivermectin was efficacious in inhibiting avian infectious bronchitis virus (IBV, a coronavirus) replication in…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach</strong> - CONCLUSION: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly M^(pro) protein and spike glycoprotein of SARS-CoV-2.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin</strong> - CONCLUSION: Our findings suggest ruboxistaurin could reduce proinflammatory and tissue-damaging consequences of neutrophils during disease, and since it has completed phase III trials for other indications without safety concerns, it is a promising and novel therapeutic strategy for COVID-19.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 version)</strong> - As the first targeted biotherapy for asthma, Omalizumab, was officially approved in China in August 2017, and was applied in clinical practice since March, 2018. Dozens of experts in Respirology and Allergy from China fully discussed the important clinical issues on the use of Omalizumab in allergic asthma by referring to the relevant publications over the world and the first version of consensus published in March 2018. Until now, over 30, 000 allergic asthma patients have received the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Single and combined effects of antibiotics and nanoplastics from surgical masks and plastic bottles on pathogens</strong> - Over the last decade, pollution of plastics and antibiotics has increased in its threat to the environment and human health. However, very limited information is available concerning impact of co-presence of plastics and antibiotics on environment and human health. Moreover, the potential ingestion and inhalation of nano(micro)plastics due to the disposable materials has dramatically increased. With the outbreak and spread of the COVID-19 in the world, disposable surgical masks and plastic…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2</strong> - CONCLUSION: This knowledge could further help understanding SARS-CoV2 infection and anti-viral mechanisms of plant-based therapeutics.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Platelet reactivity testing in peripheral artery disease</strong> - CONCLUSION: Although platelet functional tests may be simple to use, clinical trials thus far have failed to show benefit from therapy adjustments based on test results. Clinicians should be cautioned against relying on this test result alone and should instead consider a combination of laboratory, clinical, and patient-specific factors when adjusting P2Y12 inhibitor therapy in clinical practice.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials</strong> - CONCLUSION: Colchicine treatment decreased CRP levels and COVID-19 severity, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected. Thus, clinical trials need to be carried out that allow effective evaluation of colchicine in COVID-19 patients.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors</strong> - The C-type lectin receptors DC-SIGN and L-SIGN bind to glycans on the SARS-CoV-2 spike glycoprotein and promote trans- infection of ACE2-expressing cells. We tested C2 triazole-modified mono- and pseudo-di-mannosides as inhibitors of DC/L-SIGN binding to a model mannosylated protein (Man-BSA) and to SARS-CoV2 spike, finding that they inhibit the interaction of both lectins with the spike glycoprotein in a Surface Plasmon Resonance (SPR) assay and are more potent than mannose by up to 36-fold…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study</strong> - The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is posing a serious public health threat worldwide in the form of COVD-19. Herein, we have performed two-dimensional quantitative structure-activity relationship (2D-QSAR) and three-dimensional pharmacophore modelling analysis employing inhibitors of 3-chymotrypsin-like protease (3CLpro), the leading protease that is crucial for the replication of SARS-CoV-2. The investigation aims to identify the important structural…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor</strong> - The COVID-19 pandemic spurred a broad interest in antiviral drug discovery. The SARS-CoV-2 main protease (M ^(pro) ) and papain-like protease (PL ^(pro) ) are attractive antiviral drug targets given their vital roles in viral replication and modulation of host immune response. Structurally disparate compounds were reported as M ^(pro) and PL ^(pro) inhibitors from either drug repurposing or rational design. Two polyphenols dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) were recently reported as…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study</strong> - CONCLUSION: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (&gt;6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Impact of COVID-19 lockdown on the atmospheric boundary layer and instability process over Indian region</strong> - The abrupt reduction in the human activities during the first lockdown of the COVID-19 pandemic created unprecedented changes in the background atmospheric conditions. Several studies reported the anthropogenic and air quality changes observed during the lockdown. However, no attempts are made to investigate the lockdown effects on the Atmospheric Boundary Layer (ABL) and background instability processes. In this study, we assess the lockdown impacts on the ABL altitude and instability…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>MACHINE LEARNING TECHNIQUE TO ANALYZE THE WORK PRESSURE OF PARAMEDICAL STAFF DURING COVID 19</strong> - Machine learning technique to analyse the work pressure of paramedical staff during covid 19 is the proposed invention that focuses on identifying the stress levels of paramedical staff. The invention focuses on analysing the level of stress that is induced on the paramedical staff especially during pandemic. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN353347401">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CBD Covid 19 Protection</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU353359094">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>沼泽红假单胞菌5-氨基乙酰丙酸合成酶突变体及应用</strong> - 本发明公开了沼泽红假单胞菌5‑氨基乙酰丙酸合成酶突变体及应用，所述沼泽红假单胞菌5‑氨基乙酰丙酸合成酶突变体的氨基酸序列如SEQ ID NO.1所示。本发明的沼泽红假单胞菌5‑氨基乙酰丙酸合成酶突变体不仅相较于未突变的5‑氨基乙酰丙酸合成酶提高了酶活性，而且还提高了解调较高浓度血红素反馈抑制的能力，这使得本发明的宿主细胞生产5‑ALA的能力得到显著提升，约提升了40%。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN355482196">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>荚膜红细菌5-氨基乙酰丙酸合成酶突变体及应用</strong> - 本发明提供了一种荚膜红细菌5‑氨基乙酰丙酸合成酶突变体及应用，荚膜红细菌5‑氨基乙酰丙酸合成酶突变体的氨基酸序列如SEQ ID NO.1所示。本发明的荚膜红细菌5‑氨基乙酰丙酸合成酶突变体与野生型的荚膜红细菌5‑氨基乙酰丙酸合成酶相比，在宿主细胞中对5‑氨基乙酰丙酸产量提升约22%；在20μM血红素存在下，突变型5‑氨基乙酰丙酸合成酶C201A能够保持较高的相对酶活。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN355482165">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>METHOD AND SYSTEM FOR IMPLEMENTING IMPROVED GENERALIZED FUZZY PEER GROUP WITH MODIFIED TRILATERAL FILTER TO REMOVE MIXED IMPULSE AND ADAPTIVE WHITE GAUSSIAN NOISE FROM COLOR IMAGES</strong> - ABSTRACTMETHOD AND SYSTEM FOR IMPLEMENTING IMPROVED GENERALIZED FUZZY PEER GROUP WITH MODIFIED TRILATERAL FILTER TO REMOVE MIXED IMPULSE AND ADAPTIVE WHITE GAUSSIAN NOISE FROM COLOR IMAGESThe present invention provides a new approach is proposed that includes fuzzy-based approach and similarity function for filtering the mixed noise. In a peer group, the similarity function was adaptive to edge information and local noise level, which was utilized for detecting the similarity among pixels. In addition, a new filtering method Modified Trilateral Filter (MTF) with Improved Generalized Fuzzy Peer Group (IGFPG) is proposed to remove mixed impulse and Adaptive White Gaussian Noise from Color Images. The modified trilateral filter includes Kikuchi algorithm and loopy belief propagation to solve the inference issues on the basis of passing local message. In this research work, the images were collected from KODAK dataset and a few real time multimedia images like Lena were also used for testing the effectiveness of the proposed methodology. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN351884428">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种病毒核酸提取无醇裂解液、试剂盒及提取方法</strong> - 本发明公开了一种病毒核酸提取无醇裂解液、试剂盒及提取方法。本发明病毒核酸提取无醇裂解液由胍盐、无机盐、表面活性剂和缓冲液组成；所述胍盐为异硫氰酸胍和盐酸胍中的任一种或两种；所述无机盐为氯化钠和氯化钾中的任一种或两种；所述表面活性剂为聚乙二醇和吐温20；所述缓冲液的pH值为7.5~8.5。本发明可有效避免传统核酸提取裂解液中醇类挥发或刺激性气味对人体造成伤害；配制方法简单，无有毒化学试剂，安全无污染，既可手工操作提取，也可用于自动化平台；与有醇裂解液相比，病毒核酸检测的灵敏度相当，准确度一致，线性范围相当。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN355413628">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗</strong> - 本发明涉及用于预防SARS‑CoV‑2奥密克戎株的腺病毒载体疫苗。本发明采用密码子偏好性进行优化得到新的S基因序列，其能高效在人源细胞内高效表达，免疫机体后可高效表达S抗原，产生针对奥密克戎株SARS‑CoV‑2的中和抗体，可以有效保护机体免受奥密克戎株的侵染。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN355022285">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>表达SARS-CoV-2奥密克戎突变株病毒抗原肽的核酸序列及其应用</strong> - 本发明提供表达SARS‑CoV‑2奥密克戎突变株病毒抗原肽的核酸序列及其应用。奥密克戎株原始的S基因序列蛋白不能有效在细胞内高效表达；本发明采用密码子偏好性进行优化得到新的S基因序，使其能高效在人源细胞内高效表达，产生相应的多肽，诱导产生相应的免疫保护反应，为SARS‑CoV‑2奥密克戎株的疫苗的研发提供基础。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN355022274">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A STUDY ON MENTAL HEALTH, STRESS AND ANXIETY AMONG COLLEGE STUDENTS DURING COVID-19</strong> - SARS-Cov-2 virus causes an infectious disease coronavirus(COVID-19).The Students life is made harder by COVID-19.The human reaction that happens normally to everyone through physical or emotional tension is stress. Feeling of angry, nervous and frustration caused through any thought or events leads to stress. As college closures and cancelled events, students are missing out on some of the biggest moments of their young lives as well as everyday moments like chatting with friend, participating in class and cultural programme. For students facing life changes due to the outbreak are feeling anxious, isolated and disappointed which lead them to feel all alone. We like to take the help of expert adolescent psychologist to find out the techniques to practice self-care and look after their mental health. We would like to find out whether techniques used reduce the anxiety and stress among Engineering Students. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN351884923">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU351870997">link</a></p></li>
</ul>
<script>AOS.init();</script></body></html>

470
archive-daily-dose/06 April, 2022.html Normal file
View File

@ -0,0 +1,470 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>06 April, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Three Republicans for Ketanji Brown Jackson</strong> - The statements of support from Senators Collins, Murkowski, and Romney countered the blast of bitter fantasies from their colleagues on the Judiciary Committee. - <a href="https://www.newyorker.com/news/daily-comment/three-republicans-for-ketanji-brown-jackson">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Putin’s War Gives America a Chance to Get Serious About Refugees</strong> - The climate crisis will produce a huge wave of migrants, and we’re not ready. - <a href="https://www.newyorker.com/news/daily-comment/putins-war-gives-america-a-chance-to-get-serious-about-refugees">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Joe Manchin Can’t Shoot Down the Logic of a Wealth Tax</strong> - Taxing unsightly agglomerations of wealth directly is an idea whose time has come. - <a href="https://www.newyorker.com/news/our-columnists/joe-manchin-cant-shoot-down-the-logic-of-a-wealth-tax">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Many Secrets of Jamaica Bay in “Greywater”</strong> - A filmmaker sets out to investigate a poaching ring and discovers a tangle of environmental-justice issues in the New York City waterway. - <a href="https://www.newyorker.com/culture/the-new-yorker-documentary/the-many-secrets-of-jamaica-bay-in-greywater">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bruce Willis’s Minimalist Star Power</strong> - Long before aphasia affected his performances, Willis brought a misunderstood effortlessness to his best movie roles. - <a href="https://www.newyorker.com/culture/cultural-comment/bruce-williss-minimalist-star-power">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Jerrod Carmichael’s new comedy special is everything Louis CK’s Sincerely is not</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/uxF-
NOGBbMVJYRQSzUAC1wRGDUg=/480x0:1920x1080/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/70716120/jerrod_carmichael_rothaniel_ka_1920_0.0.jpeg"/></figure></li>
</ul>
<figcaption>
Comedian Jerrod Carmichael. | Courtesy HBO
</figcaption>
<pre><code>&lt;/figure&gt;</code></pre>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Grammy or no Grammy.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LRW2xb">
Jerrod Carmichael’s new HBO special <em>Rothaniel</em>, directed by Bo Burnham and filmed on a recent wintry night at the Blue Note Jazz Club in New York, is a quiet comedy revelation. Carmichael first delves into the skeletons in his family’s closet (in short, prolific cheating from the men in his family), then reveals his own big secret: He’s gay. He takes viewers through a gentle coming-out narrative, interspersed with occasional questions and reassurances from the audience.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="60znwh">
“I’m trying to be very honest because my whole life was shrouded in secrets,” Carmichael says at the end of the evening, “and I figured the only route I hadn’t tried was the truth.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XxuYtE">
Carmichael’s approach to his coming-out is to turn his comedy stage into a place of healing and acceptance, in which the audience becomes his confessors. If Hannah Gadsby’s 2018 special <a href="https://www.vox.com/culture/2018/7/5/17527478/hannah-gadsby-nanette-comedy"><em>Nanette</em></a> has pushed comedians to balance <a href="https://www.vox.com/culture/22922007/comedy-isnt-funny-moral-joe-rogan-whitney-cummings-
moses-storm-che-diaz">serious themes with the need to make people laugh</a>, <em>Rothaniel</em> is a new mediated space altogether — half comedy, half interactive therapy session. The jazz club setting lends an even more intensely improvisational feeling to Carmichael’s monologuing. It’s comedy as melisma, maybe, complete with stammers, pauses, and his admission that he’s still working some things out — both the comedy bits and the emotional bits.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="78ZgES">
The name of the special refers to a layered metaphor for that process — it’s the given name he’s tried to erase for years but has finally accepted as a messy part of himself. It’s perhaps lighter on laughs than Carmichael’s previous specials, but his particular, unhurried power has always come from a lack of neuroses about audience reaction, coupled with a willingness to deliver what he sincerely has to give. Here, he performs the mental and emotional toll of trying to repress something so huge until it comes spilling out — until honesty is the only thing you have left.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="b3ajdG">
Two days after <em>Rothaniel</em>’s release, <a href="https://www.rollingstone.com/culture/culture-
news/louis-c-k-grammys-sexual-misconduct-1331976/">Louis C.K. won a Grammy</a> for Best Comedy Album, for <em>Sincerely, Louis CK</em>, filmed in Washington, DC, in March 2020 and released to fans on his personal website a month later. The Grammy win comes four and a half years after <a href="https://www.vox.com/culture/2017/11/9/16629400/louis-ck-
allegations-masturbation">multiple women in comedy made allegations</a> of sexual misconduct against C.K., causing him to issue a demonstrative apology in which he vowed to “step back and take a long time to listen.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yLy24B">
The title of C.K.’s special might lead you to believe that it, like <em>Rothaniel</em>, contains a key to its contents — that C.K. is perhaps ready to level with audiences about his conduct and open up about what’s changed since the scandal. Instead, he seems to armor himself against a world he’s decided to battle. In conversation with <em>Rothaniel</em>, <em>Sincerely</em> offers us a striking glimpse of how “confessional” comedy means very different things depending on who’s doing the confessing.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qsax7j">
The hugely delayed nature of the Grammys, delayed even more thanks to Covid-19, means watching <em>Sincerely</em> now, two years after its release, feels like an anachronism: C.K.’s performance was just days prior to the beginning of the 2020 lockdown, for an audience that perhaps understood the concept of an enclosed confessional space very differently than Carmichael’s intimate nightclub audience did two years later. The contrast between the two shows couldn’t be more striking: Carmichael softly working through his coming-out process to a small venue of often utterly silent listeners; C.K. greeting a crowd of 1,500 people who gleefully applaud his every dictum on pedophilia, disability, gay sex, and his sexual misconduct.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8gRFYP">
Throughout his decades of standup, and especially during the run of his <a href="https://www.vox.com/culture/2019/12/17/20997966/louie-best-tv-shows-2010s-louis-ck-allegations-fx">once- influential TV show, <em>Louis</em></a>, C.K. favored material that tended toward observational empathy, with self- deprecation always tempered by a basic layer of goodness. Jokes about dating, for instance, looked honestly at <a href="https://www.youtube.com/watch?v=yRzs7v0do_Q">women’s reasonable fear of men</a>; jokes about <a href="https://www.youtube.com/watch?v=nUBtKNzoKZ4">plane wifi</a> were fundamentally about how good we all have it. C.K. could be honest about his worst impulses because they were always tempered by his, and humanity’s, best.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ctbUK1">
Following his disgrace, numerous <a href="https://slate.com/culture/2020/04/louis-ck-new-stand-up-special-
sincerely-review.html">critics</a><a href="https://www.vox.com/culture/2019/12/17/20997966/louie-best-tv-
shows-2010s-louis-ck-allegations-fx"> discussed</a> how C.K. had built up a level of trust that allowed his audience to accept his darker material as part of the struggle of a man who shared their basic sense of morality. C.K. then destroyed that trust, at least for some, when he <a href="https://www.nytimes.com/2017/11/10/arts/television/louis-ck-
statement.html">admitted</a> to years of masturbating openly in front of many women in comedy. C.K. did this without their enthusiastic consent (or, in at least some cases, <a href="https://slate.com/human-interest/2017/11/louis-c-k-s-
masturbation-statement-unnervingly-misunderstands-the-concept-of-consent.html">without any apparent consent</a>), nor any regard to the huge power imbalance between them. After at least one incident, his manager <a href="https://www.nytimes.com/2017/11/09/arts/television/louis-ck-sexual-misconduct.html">allegedly attempted to silence</a> some of the women.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iMV6zh">
Once the less-than-empathetic nature of his in-person interactions was revealed, it seemed that his performance of empathy was over too. Instead, something uglier snuck in: Nine months after his promise to listen, he <a href="https://www.vox.com/culture/2018/8/28/17790532/louis-ck-scandal-comeback-comedy-
cellar-sexual-misconduct">resumed performing</a>, with his comedy taking a <a href="https://www.vox.com/2019/1/9/18172273/louis-ck-comeback-parkland-aziz-ansari-metoo">pronounced turn toward the reactionary</a>. During <a href="https://www.vox.com/2019/1/9/18172273/louis-ck-comeback-parkland-aziz-ansari-
metoo">leaked club appearances</a> from late 2018, he mocked Parkland survivors, nonbinary teens, and the loss of the “r” word. (That last one made it into the Grammy-winning special.)
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2MY4aO">
<em>Sincerely</em> seems to be primarily about insincerity — his, ours, and how foolish we’d have to be to expect anything else. He talks about wishing he could be meaner. He calls his audiences hypocrites for pretending to be morally horrified by some tasteless jokes but not others. He says he hates New York, where he lived from <a href="https://www.6sqft.com/comedian-louis-c-k-buys-
third-unit-in-west-village-brownstone/">at least 2006</a> until the implosion of his career. He makes fun of Orthodox Jews, Islam, and Japanese restaurant workers; he fantasizes about crushing the illusions of modest shopkeepers. Where once he might have pulled out a <a href="https://www.youtube.com/watch?v=7x598orzdU0">heartwarming humanist kicker</a>, <em>Sincerity</em> seems to be about establishing C.K., and his audience’s, <em>lack</em> of empathy as the default. There’s no longer a collective wish for something higher. There seems to be nothing higher left to aim for.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="A3gCsm">
At one point during the special, C.K. wonders if gay people might not prefer the days when gay sexuality was more of a taboo. Is there not, somehow, an illicit thrill in the deviance of queerness? he wonders — or if you want to look at it through another lens, from knowing people think you’re less human as a result of your sexual orientation? As a joke in isolation, it’s thoroughly whatever. But taken in the context of <em>Sincerity</em> as a whole, it’s a dick joke masquerading as an indictment, as a suggestion that queerness is a clever joke being played on the rest of us and that queer people are somehow in on it. For Louis C.K., sincerity now involves reconfiguring the world as complicit in his dishonesty — and ultimately as complicit in his misconduct.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="jEFK6m">
“You don’t want to know … who your real friends are,” C.K. says early in the special. “It’s never who you want it to be.” The obvious probing point about why some of C.K.’s better friends left him, and what kind of atonement might be necessary to restore their esteem, goes unmade.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rAGRIj">
Meanwhile, in Carmichael’s soliloquy, one of his closest friends tells him he felt “tricked” into having a gay best friend — because despite C.K.’s best efforts, the world he’s tried to reframe still threatens the most vulnerable people in it. Carmichael’s reckoning with his queerness — his family’s mixed reactions, the distance he feels from his mother, his internalized homophobia and fear, and the idea that secrecy and shame can become generational trauma — makes that abundantly clear.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="w1lDk9">
While both men are angry, stinging from private betrayals, Carmichael doesn’t externalize his discomfort in the same way. Perhaps that’s because much of this is new and raw, but perhaps it’s also because externalized anger is costlier, riskier for Black, queer men in America than it is for the average disgruntled white guy.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="N4j3eM">
Carmichael’s comedic honesty is born, in other words, from the kind of desperate need for freedom and self-expression that C.K.’s revamped comedy now seems to denigrate. Having lost the favor of his original audience but still amassing a huge amount of patronage, wealth, and power, C.K. chose to rewrite the world that disowned him rather than rewrite himself. Had he truly made good on his promise to “step back and take a long time to listen,” it’s hard to fathom him re-emerging with a worldview this cynical. But a byproduct of his weak analysis is that it makes a truly sincere inner reckoning like Carmichael’s seem that much more profound in comparison.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="BIlPvs">
C.K.’s Grammy win — not just on its face but for this particular, aggrieved album — underscores the entertainment industry’s unwillingness to <a href="https://www.vice.com/en/article/k789vn/metoo-group-
times-up-failed-sexual-assault-survivors">internalize</a> many of the lessons of Me Too. C.K.’s moment of “realness,” when he finally talks about his behavior near the end of his special, stays unsettlingly superficial, framing his behavior as an unfortunate miscommunication about a weird sexual kink.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="T9CovF">
He segues into this from his “maybe gay people wish they were still taboo” bit — that fantasy of illicit kink was merely projection, of course. His ability to look honestly at human relationships, to see them through anything but his own lens, is shot. He gets a trophy anyway, sealing his absolute privilege over the women who were brave enough to name what he did. For those women, seeing their stories reappropriated by the man who assaulted them, and then stamped with approval by the Recording Academy, no less, must be the ultimate confirmation that nothing really changes.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1Hi3VV">
His win suggests that men of great privilege, like C.K., can afford to be disingenuous about what confessional comedy really is. C.K.’s moment of so-called honesty costs him nothing. He risks nothing, and he learns nothing. <em>Rothaniel</em>, on the other hand, suggests that perhaps there’s a connection between the kind of comic who makes themselves vulnerable and open to profound interpersonal connection through their chosen medium and the kind of life experience that pushes a person toward a need for safety and acceptance in a society that marginalizes them. It suggests that there’s something higher to be gained.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yhG4N6">
C.K. might think he still needs safety and acceptance from the comedy community, but the type of worldview he evinces these days makes comedy a little bit less safe for the rest of us. The Academy might be eager to welcome C.K. back into the fold, but that just underscores the pernicious subtext of <em>Sincerely</em>: The sincerest thing about it may be its reflection of a societal structure that rewards unkindness, inequality, and denial.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GcVokM">
That might be true, but <em>Rothaniel</em> shows us that those at society’s edges still seek truth, compassion, and healing, turning to increasingly unconventional spaces as more traditional avenues for community and acceptance remain closed. Carmichael finds that healing onstage on a snowy night at the Blue Note, performing comedy as something like a new, hybrid form of slow jazz improv. That achievement, ultimately, feels far more significant to comedy than the miserable laughs of <em>Sincerely</em>. One may have won a Grammy; the other feels like a far more meaningful reward.
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A new documentary looks at women who survived domestic violence — then faced jail time</strong> -
<figure>
<img alt="" src="https://cdn.vox-
cdn.com/thumbor/eYAHKXCAM75cP4123xyGADk1n-E=/322x0:2202x1410/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/70715945/Production_Still_ASIS_01.0.jpg"/>
<figcaption>
Kim Dadou Brown, a domestic violence survivor who spent 17 years incarcerated, is now an activist for other survivors. Her story is part of the documentary <em>And So I Stayed</em>. | Daniel A. Nelson/And So I Stayed/Grit Pictures LLC
</figcaption></figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
And So I Stayed challenges the dominant narratives about abuse.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gjOT8Q">
Midway through <em>And So I Stayed</em>, Kim Dadou Brown — a survivor of domestic violence who served 17 years in prison for killing her partner — sits in a semicircle with a group of women, sharing her experiences of abuse. She relates an anecdote about a time she went to a store with her then-partner. Dadou Brown said she was wearing jeans with an intentional rip in the upper back of the thigh.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="PityDi">
When she came out of the store, her partner was angry. He asked her if she thought she was cute, and told her to turn around. When she did, Dadou Brown said, he grabbed the hole in her jeans and tore it, exposing her in public. For a moment, she was frozen in shock. Then he shoved her, and she snapped back into the moment. “There’s guys on the street,” she says, gesturing in front of her. “There’s drug dealers. There’s kids. There’s people barbecuing, like — <em>nobody said anything. No one ever did</em>.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wGCAuL">
Dadou Brown was describing her own experiences: how it felt like the people in her community would rather look away than face the uncomfortable truth of what she was living through. But she might as well have been describing a broader instinct on the part of society to turn away from, and ignore, the abuse victims in its midst. Some things have changed in the 30 years since Dadou Brown was convicted of manslaughter in the first degree. There’s greater awareness now of the difficulties domestic violence victims face in being believed, and the danger they face when trying to leave abusive relationships.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8QNppv">
Other elements of understanding have not changed, perhaps especially when a survivor says she was defending herself or responding to an abuser’s attack. The proliferation of true crime as entertainment, through television and podcasts, has only made it worse. Among the most egregious examples is <em>Snapped</em>, the Oxygen network mainstay that repackages real stories of crimes committed by women, <a href="https://www.thecut.com/2021/12/domestic-abuse-survivors-dont-just-snap.html">often in the context of domestic violence and abuse</a>, as sensationalist curios. Women who kill their partners are portrayed as devious, malevolent, out of their minds.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Flkled">
<em>And So I Stayed</em>, a documentary by filmmakers Natalie Pattillo and Daniel A. Nelson, makes the realities of domestic violence much harder to ignore, by focusing on the lived experiences of three survivors who were incarcerated for killing their partners. Dadou Brown, who was released from prison in 2008 and has since become an advocate for other survivors, is one of them; so is Tanisha Davis, a woman serving a sentence for manslaughter in New York state after stabbing her abusive partner during an attack.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="cdLxil">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="6xwghQ">
The film also follows the case of Nikki Addimando, a mother of two who was put on trial for second-degree murder for killing her longtime partner after years of abuse. The latter case (which has also been the subject of an excellent podcast, <a href="https://podcasts.apple.com/us/podcast/believe-her-official-
trailer/id1588789400?i=1000537532477"><em>Believe Her</em></a>, and <a href="https://gen.medium.com/nikki-had-proof-
shed-been-abused-but-was-it-enough-for-self-defense-bd9f196396eb">two magazine</a> <a href="https://www.newyorker.com/news/dispatch/when-can-a-woman-who-kills-her-abuser-claim-self-defense">pieces</a>) shows that even extensive evidence of abuse, in the form of photographs and reports to police and social services, were insufficient to convince a jury that her actions were justified on the night Addimando killed her partner.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hvlYf8">
The film opens with Nikki as a newborn baby, held by her father at the hospital. “We just want to go home and continue to be a new family,” her dad says. This scene of familial tenderness is juxtaposed with the audio of a call from the Dutchess County Jail. Addimando, now an adult, is speaking with her father while she awaits trial, contemplating the possibility that she might spend the rest of her life in prison.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qJ5kwn">
She asks: “There is no self-defense law here, is that what I’m understanding?” And, “There was a gun in my face, what else was I supposed to do?” Addimando’s father tries his best to comfort her. “Your daddy loves you,” he says, “remember that.” By the time of the call, Addimando is not just a daughter but a mother now, too. Some of the most affecting and heartbreaking moments of the documentary come in the form of conversations with her young children, who cry as they speak to their mom, not understanding why, despite how much they love each other, they aren’t able to be together.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="X9O1fW">
The film features an interview with Addimando’s therapist, Sarah Caprioli, who attests to the “regular bruising on her face, her arms … sometimes around her neck and around her chest,” along with pictures of Addimando’s reddened wrist, and dark bruises on her neck and cheekbone. It shows the dashcam footage of Addimando the night she was picked up by police, stepping out of her car in a state of shock, telling a police officer, “I stayed with him for as long as I could have,” and later, “He’s a good dad, and so I stayed.” We hear the audio of the 911 call Davis made the night she stabbed her partner, the anguish and terror in her voice as she screams her address and begs for help, while a 911 call operator impatiently tells her to calm down.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="oyVAoH">
The filmmakers, Pattillo and Nelson, were both graduate students at the Columbia Journalism School when Pattillo <a href="https://narratively.com/she-killed-her-
abuser-before-he-could-kill-her-then-served-17-years-now-shes-taking-on-the-system/">started writing about</a> the incarceration of women who have survived intimate partner violence. As a survivor who lost her sister to domestic violence, Pattillo wanted to give a voice to women who, through the legal process (and in true crime narratives), are often robbed of their truths.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="BRlbay">
“Having been in an abusive relationship myself, I knew it’s very much life or death, there’s no in-between when those power and control dynamics are at play. I couldn’t understand that that’s what we thought justice was, to incarcerate and criminalize people who were literally just wanting to live,” she says. “We were looking for people to see survivors, to hear their hopes and dreams, their grief, as much as they were willing to share. All the things we weren’t able to see in the courtroom.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JDFQrz">
It’s not just the survivors’ grief that animates the film. Much of its forward momentum is provided by Dadou Brown, who aptly describes the pain of being abused and then disbelieved by the legal system. “I felt that I was screwed over by the same system that I used to go to for help,” Dadou Brown told me in an interview, noting that she had police reports and hospital records that corroborated her prior abuse.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="CsdXhg">
As the film follows her, Dadou Brown spends much of her free time post-conviction pushing for the passage of a law that would allow courts to <a href="https://www.ils.ny.gov/files/NYC%20-%20What%20is%20DVSJA.pdf">consider the experiences</a> of domestic violence survivors in resentencing them. The Domestic Violence Survivors Justice Act (DVSJA) became law in New York in 2019, thanks in large part to the advocacy of survivors like Dadou Brown and others, and the film follows her as she provides comfort to Davis’s and Addimando’s families. By the end of the film, Davis has been released under the DVSJA after the judge in the case viewed footage about Davis prepared by the filmmakers, but Addimando has not — the judge in her case ruled that she was ineligible to be sentenced under the new law.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="RrClQN">
In 2021, though, an appeals court ruled that Addimando was in fact eligible for the DVSJA and reduced her sentence from 19 years to life to seven-and-a- half years, making her eligible for release in 2024; supporters are <a href="https://westandwithnikki.com/case1">urging</a> New York Gov. Kathy Hochul to grant her clemency immediately. Pattillo and Nelson have since been approached by lawyers for other survivors with requests to make short videos to help support their petitions for legal relief, and they are partnering with theaters, legal organizations, and nonprofits to screen their movie.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="WTEY6I">
The filmmakers understand that the survivors don’t necessarily need anyone to speak for them, they just need to be heard and believed. These acts of witnessing — whether it’s by the people who ignored Dadou Brown, the viewers of <em>Snapped</em>, or those who watch <em>And So I Stayed</em> — are not neutral. In focusing on the stories of survivors, the filmmakers challenge viewers to reconsider some of the dominant narratives about women and violence. They suggest that we cannot continue to look the other way.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XGvVTn">
At her sentencing, Addimando told the court, “I wish more than anything that this had ended another way. If it had, I wouldn’t be in this courtroom. But I wouldn’t be alive either. And I wanted to live. I wanted this all to stop. I was afraid to stay, afraid to leave, afraid that nobody would believe me. Afraid of losing everything. This is why women don’t leave. I know killing is not the solution, and staying hurts, but leaving doesn’t mean living. So often we end up dead, or where I end up standing,” she said. “Alive, but still not free.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bxrL4r">
And So I Stayed i<em>s playing in select theaters. To find a screening or to host your own, contact the filmmakers </em><a href="https://andsoistayedfilm.com/upcomingscreenings"><em>here</em></a>.
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What immunocompromised people need to know right now</strong> -
<figure>
<img alt="" src="https://cdn.vox-
cdn.com/thumbor/iEKXItDoknVRoRBbh0-NXOUVzZc=/353x0:6217x4398/1310x983/cdn.vox-
cdn.com/uploads/chorus_image/image/70715900/1237873890.0.jpg"/>
<figcaption>
A woman wearing a face mask walks on a busy street in New York on January 19, 2022. | Wang Ying/Xinhua via Getty Images
</figcaption>
</figure></li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
There’s a spectrum of risk among this group, and a lot of tools to help them.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LFqKe1">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="QEz2FJ">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2cxgd8">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="B0lXfH">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yp2diu">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qlwsVa">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="imkBhP">
Fredrick Wilson, a spine doctor at the Cleveland Clinic, was asleep at home in June 2020 when he had a massive heart attack that destroyed more than three-quarters of his heart tissue. He was lucky to survive the ambulance ride to the hospital.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="u2yu1i">
Until then, Wilson, now 66, had been a healthy cyclist who took no prescription drugs. But after the attack, he needed a heart transplant, and with it, 33 pills to swallow a day, including powerful immunosuppressants to prevent his immune system from attacking his transplanted heart. These drugs help keep his new heart pumping, but they also make it harder for his body to fight off infections. They put him at high risk for both catching Covid-19 and having severe outcomes from the infection.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="igmVCY">
As Covid-19 stutters into endemicity, the <a href="https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-immunocompromised-etr.html">more than 7 million</a> Americans with weakened immune systems, including Wilson, are left making hard choices that others don’t face. He feels conflicted: He misses taking care of his longtime patients and teaching junior colleagues his craft. But he’s also afraid to die from Covid-19 after such a miraculous survival.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="lw7cZH">
“Every time I go to the office, I’m going to feel some risk involved, and I’m not really that comfortable with it,” he said. But, he added, “I’m just not ready to stop seeing patients just yet.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wFgwJ9">
Even for a doctor, making decisions as an immunocompromised person is difficult — especially now. There’s no obvious guidebook for this group, in part because immunocompromised states are almost as diverse as the individuals who cope with them. While the risks associated with these conditions are not uniform, many immunocompromised people are now making decisions under a <a href="https://www.theatlantic.com/health/archive/2022/02/covid-pandemic-immunocompromised-risk-vaccines/622094/">blanket of fear</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iKrnE1">
Helping people with weakened immune systems navigate this stage of the pandemic means recognizing that the group contains a large spectrum of risk — but even those at more risk now have tools that allow them to be proactive about their safety, and both individual and collective actions can help protect them.
</p>
<h3 id="iytjwL">
There’s a wide spectrum of risk among immunocompromised people
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="4uyean">
It’s really hard to assess the exact risk an immunocompromised person faces. That’s partly because “immunocompromised” is a catch-all term for a complex group of conditions. The immune system consists of many interrelated parts, and weaknesses in different components of it can lead to different levels of risk.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3kav1I">
“It’s not like there is a clear category of ‘you’re immune compromised’ and ‘you’re not at all’ — there’s a gradient,” said Dimitri Drekonja, an infectious disease doctor at the University of Minnesota.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="IrpkbD">
Immune systems can be weakened in different ways — via disease, such as advanced or untreated HIV; by treatments for certain medical conditions, such as medications used to treat rheumatoid arthritis, multiple sclerosis, and some cancers; or by medications that target normal immune systems in transplant patients, to <a href="https://www.webmd.com/a-to-z-guides/organ-transplant-after-the-transplant">prevent them from attacking new organs</a>, or immune system components, such as in stem cell transplants.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="eGTdIg">
When it comes to Covid-19, the important question for immunocompromised people is whether their immune system’s specific vulnerability places them at higher risk for either infection with or severe disease due to the coronavirus.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="NaM8WY">
Immunocompromised people, overall, are thought to be at particular risk for Covid-19 because the SARS-CoV-2 virus is so new, said Christine Koval, who leads the transplant infectious disease team at the Cleveland Clinic.<strong> </strong>They’re also at relatively higher risk for severe outcomes from common cold and flu viruses, but their immune systems have encountered these viruses before. SARS-CoV-2 is too new for their immune systems to offer much protection against it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="U19pHQ">
The data is mixed on which immunocompromised people face the greatest danger when it comes to Covid-19, in large part because many in this group are older or have other medical conditions that raise the risk of severe disease.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="qsQNBs">
Experts generally agree <a href="https://www.uptodate.com/contents/covid-19-considerations-in-patients-with-
cancer?search=covid%20immunocompromised&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1#H346374680">Covid-19 risk is elevated</a> for people with cancers of the blood or immune systems (like leukemia, lymphoma, and multiple myeloma), lung cancer, advanced or progressive cancer, recent stem cell transplants, and advanced or untreated HIV. Those actively receiving chemotherapy that reduces bone marrow activity, and people with <a href="https://primaryimmune.org/news/doctors-provide-updates-covid-19-and-pi">some primary immunodeficiencies</a> are also in the highest-risk category.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="QHnwN0">
The CDC’s <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html#mod">“moderately to severely immunocompromised”</a> designation, created largely for the purposes of allocating Covid-19 vaccines, includes these high-risk categories. But it also includes more ambiguous ones, including people taking other immunosuppressive medicines and those who have received organ transplants, conditions whose risk scientists <a href="https://pubmed.ncbi.nlm.nih.gov/32766815/">don’t</a> <a href="https://pubmed.ncbi.nlm.nih.gov/34117116/">understand</a> as well.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9wFqlb">
Researchers have not yet developed a unifying theory to explain why certain immunocompromised states raise the risk from Covid-19, but many have proposed an important role for B cells. These immune cells are responsible for producing the antibodies key to the immune system’s sentinel function, which identifies invading germs and signals the need for a counterattack. That makes them critical to the body’s defenses against new pathogens; because people taking medicines that dampen these cells’ activity have a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846615/">less robust vaccine response</a> and <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150936/#:~:text=Results%3A,range%20of%20underlying%20disease%20states.">higher risk for severe infection or death</a> when it comes to Covid-19, scientists think there is a relationship between B cell function and risk.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KZI6tZ">
When a medical condition or treatment weakens the entire immune system, it also weakens B cells; that could explain why people with blood cancers, stem cell transplants, and advanced HIV are at higher risk.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ppe5uZ">
However, B cell dysfunction doesn’t explain all of the risk immunocompromised people face, said David Hafler, a neurologist and immunobiologist at the Yale School of Medicine. In some people with weakened B cells (for example, those who take the prescription medication rituximab) other parts of the immune system seem able to pick up the slack — but not in everyone.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OB5Z9o">
Ultimately, that makes it hard to sort individuals definitively into risk categories.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SzpJAb">
Hafler attributes some of this variability to the “immune lottery” — that is, the role of genetics in determining individual strengths and vulnerabilities in each person’s defenses. “Everyone has a different immune system,” he said, which makes it hard to ascertain why some people have severe Covid-19 infections while others do not, without understanding underlying genetic differences. (It is possible to test for the presence and level of SARS-CoV-2 antibodies in the blood, which are products of the immune system’s defense against the virus. But these tests don’t tell you how protected you are — or are not — from an infection.)
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bEiZtL">
Megan Ryan, an advocate for people with primary immunodeficiencies, who herself has common variable immunodeficiency, said the individually variable nature of immunocompromised states makes it particularly important that higher-risk people get their information from health care providers who know them — not from the public square. “It is a confusing time,” she said, “because there’s a lot of people who are either experts or self-proclaimed experts — there’s just a lot of voices in the system.” She recommended seeking medical advice from the health care team that knows you best “rather than crowdsourcing an answer,” she said.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wPNRqC">
That’s also the best advice for people concerned they have an undiagnosed immune system problem: get evaluated by a health care provider — ideally, one who knows you well.
</p>
<h3 id="JYYiaI">
What immunocompromised people and their communities can do
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="DViD9p">
While immunocompromised people should address questions about individual risk and recommendations with their health care providers, they should also be aware of the tools available to protect them from Covid-19’s worst outcomes.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7iZDaO">
<strong>1) Vaccines and masks: </strong>Vaccination remains a key component of prevention. In addition to the two-shot initial vaccine series and the first booster shot, a second booster dose has been approved and is <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-
shot.html?s_cid=11706:cdc%20covid%20booster:sem.ga:p:RG:GM:gen:PTN:FY22">recommended</a> for immunocompromised people. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846615/">Immunocompromised people</a> are somewhat less protected by vaccines than people with normal immune systems, but the protection isn’t zero.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vuhYa7">
“Except in the most extreme circumstances, they do have some protection if they’ve followed the recommendations for the vaccinations,” Koval said.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="V6OKNG">
Wearing a properly fitted N95 mask also provides <a href="https://www.pnas.org/doi/10.1073/pnas.2110117118">excellent</a> <a href="https://www.cidrap.umn.edu/news-
perspective/2021/10/commentary-what-can-masks-do-part-1-science-behind-covid-19-protection">protection</a> during casual contact with others, even when they are unmasked. Koval said household members of immunocompromised people should also mask up in public places to avoid transmitting the virus when back at home.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hLt3uJ">
<strong>2) Antibody treatments: </strong>A long-acting preventive antibody formulation called Evusheld should offer some hope to immunocompromised people hoping for a higher degree of protection. Early data showed this therapy reduced the risk of symptomatic infection in unvaccinated high-risk adults (including but not limited to immunocompromised people)<strong> </strong>by <a href="https://www.fda.gov/media/154701/download">77 percent</a>, and that the protective effect may last long enough to allow recipients six months between doses.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="I2QJOd">
But due to a short supply and confusion among health care providers about who should receive the drug, many immunocompromised people who want the drug have been <a href="https://www.nytimes.com/2022/03/06/us/politics/evusheld-covid-treatment.html">unable to get it</a>. Currently, the cost of this therapy itself is <a href="https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/mAb-cost-
and-coverage-faqs.aspx">covered by the federal government</a>, although the cost of infusing it varies by insurance plan. If Congress does not pass the latest, condensed version of a <a href="https://www.vox.com/coronavirus-
covid19/23009783/covid-19-relief-funding-bill-senate-vaccines">Covid-19 relief bill</a>, Evusheld may become harder to <a href="https://www.whitehouse.gov/briefing-room/statements-releases/2022/03/15/fact-sheet-consequences-of-lack-of-
funding-for-efforts-to-combat-covid-19-if-congress-does-not-act/">access</a> in the future.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FnTl3k">
<strong>3) Oral antivirals: </strong>If they do get infected, immunocompromised people may also benefit from treatment with <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-
first-oral-antiviral-treatment-covid-19">Paxlovid</a>, an oral antiviral medication people take early on during Covid-19 infections to prevent more severe illness. However, this medication cannot be taken with some other medicines commonly prescribed to treat high blood pressure and high cholesterol, so it will be off-limits to some immunocompromised people.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zApVCq">
<strong>4) Services to connect patients with medications: </strong>A new <a href="https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/">Covid-19 therapeutics locator</a> created by the federal government aims to help health care providers more effectively link treatments with patients who stand to benefit most from their protective effects.<strong> </strong>
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="21tqmb">
Immunocompromised people can also use another new federal website geared toward patients to identify <a href="https://covid-19-test-to-treat-locator-
dhhs.hub.arcgis.com/">the nearest “test-to-treat” location</a>, where people can be tested for Covid-19 and if positive, get treated with either Paxlovid or molnupiravir, another antiviral medication that’s less effective than Paxlovid but doesn’t interact with other medications.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="F3U1q9">
<strong>5) Non-immunocompromised people can be thoughtful, and policies can be proactive: </strong>Although mask mandates are no longer in effect in most of the US, an accommodating attitude from the general public — and policies that encourage a culture of consideration in places where there’s no way to remain masked around others — can help maximize safety for immunocompromised people.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="a1VMov">
Workplace lunchtimes are challenging for both adults and kids, said Drekonja: “I have a private office where I can go eat lunch, but many people don’t — they have a break room,” he said, or in the case of school children, a cafeteria. “They don’t get a magic forcefield for the 20 minutes that they’re eating — what do they do?” he said.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gFDlWB">
There are no easy answers on how to minimize exposure for immunocompromised people in these situations, especially in places where it’s too cold to be outside for half the year. However, improving ventilation and air filtration and maximizing vaccination rates and masking among those sharing air space with high-risk people in these scenarios would help.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="OijNCo">
Of course, the best way to reduce the risk Covid-19 poses to immunocompromised people is to reduce transmission of the SARS-CoV-2 virus altogether. The more we collectively take steps to avoid large waves of transmission going forward, the faster we lower the risk for everyone.
</p>
<h3 id="mR3HQU">
Assessing your risk tolerance and personal priorities might ease decision-making
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zCCgvs">
At this stage of the pandemic, immunocompromised people have several tools to protect themselves from Covid-19. Still, some decisions remain difficult to think through. There is no way to know the absolute risk of any situation, and there is no way to do away with risk entirely. The uncertainty can feel unsettling and exhausting.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hCpi9z">
People who are able to balance caution and uncertainty with joy and meaningful activity are having an easier time right now. Personal preferences and priorities help determine how much these two years have felt like a loss, said Drekonja: If you’re someone who was looking forward to a retirement full of nights at the opera and dinners out, it’s been brutal — but if you’re a homebody who just wants to read and go for walks outside, “it’s not a big deal,” he said. “Part of it is, what’s your baseline?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3W7W4H">
Many people “get this message that they’re at such high risk for death that they can’t really function normally in the world,” said Koval. But she doesn’t believe that’s realistic.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="i9H1pt">
“It is uncomfortable to live in these muddy situations, particularly when we’re two years in and the type of data that we have is just not that helpful for patients, and for us to help them make informed decisions,” Koval said. “I’m hoping it gets better.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kYs0m1">
Fredrick Wilson, the doctor who suffered the heart attack, also hopes it gets better — ideally, in time to let him do just a little more of his life’s work before retiring. He would be reassured by proof that a combination of vaccines and antivirals would be 100 percent effective at preventing coronavirus deaths, but that proof does not yet exist, and it’s unclear if it ever will. Meanwhile, he’s stayed up to date on his booster shots, and recently received a dose of Evusheld. He expects to start seeing patients again in early May.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SxvbtC">
Wilson recalls his earliest days of practice, when gaps in knowledge about the cause of AIDS made many clinicians afraid to care for patients. That uncertainty wasn’t all that different from the way the Covid-19 landscape feels right now, he said: “We don’t know all the answers yet — and it’s just going to take some time.”
</p>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CBI registers preliminary enquiry against IOA chief Narinder Batra for alleged ‘misuse’ of Hockey India funds</strong> - It was alleged in the complaint that ₹35 lakh of Hockey India funds was used for personal benefits of Batra</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IPL 2022 | Warner, Nortje and Stoinis all available ahead of Delhi Capitals-Lucknow Super Giants clash</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Explained | Who is Pravin Tambe, the subject of Hotstar’s new cricket biopic?</strong> - After years of playing club cricket in Mumbai, the leg-spinner made his IPL debut in 2013 at the age of 41</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sindhu, Srikanth sail into Korea Open second round</strong> - Sindhu will next meet Japan's Aya Ohori, while Srikanth will be up against Israel's Misha Zilberman</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Australia beats Pakistan by 3 wickets in one-off Twenty20</strong> - Australia rounded off its first tour to Pakistan in 24 years with a three-wicket victory in the one-off Twenty20</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mumbai reports India’s first case of Omicron’s XE recombinant variant</strong> - A case of the Kappa variant was also detected</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Muslim shopkeeper on Chennakeshava temple premises in Karnataka told to shut shop</strong> - Executive officer of the temple issued a notice for closure as per a rule in Endowment Act 2002</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Keltron crosses ₹500-cr. turnover</strong> - Makes net profit of ₹20 crore</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Govt. to raise ₹15,000 crore through open market borrowings in first quarter</strong> - RBI releases indicative calendar of borrowings by States/UTs</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Veteran Bengali writer wins coveted O. Henry Award for 1977 story</strong> - Sahitya Akademi awardee Amar Mitra wrote Gaonburo when he was 26 years old</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ukraine war: Destruction in the Ukrainian town of Borodyanka</strong> - Police say there could be hundreds of people buried under rubble of blocks destroyed by Russian attacks.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bucha killings: ‘I wish they had killed me too’</strong> - A family tells the BBC how Oleg Abramov, a welder in Bucha, was shot dead outside his home.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ukraine War: Western leaders to impose further sanctions on Russia</strong> - The Ukrainian president expressed frustration ahead of new EU and US sanctions being announced.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ukraine war: Zelensky tells UN of horrors of Russian invasion</strong> - Ukraine’s president says Russia must be held accountable for civilian deaths in northern Ukraine.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>War in Ukraine: ‘I saw a Russian soldier shoot my father dead in Bucha’</strong> - Teenager’s account adds to growing evidence of atrocities allegedly committed by Russian soldiers in Bucha.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>That time when Soviet rocket scientists nearly nuked New York City</strong> - “The world was standing on the brink of thermonuclear war.” - <a href="https://arstechnica.com/?p=1845557">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sonic 2 film review: This year’s Super Mario film has a new bar to clear</strong> - Speed, style, laughs, and surprises: Sonic holds on to all his golden rings this time. - <a href="https://arstechnica.com/?p=1845746">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Comcast wanted man to pay $19,000 after falsely advertising service on his street</strong> - Comcast’s ordering website falsely stated that Internet service was available. - <a href="https://arstechnica.com/?p=1844282">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IPCC report: The next few years are critical</strong> - New report on climate solutions is good news, bad news, and a to-do list. - <a href="https://arstechnica.com/?p=1846017">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Biden steps up federal efforts to address long COVID</strong> - Up to 23 million Americans may have long-term effects, such as shortness of breath, fatigue. - <a href="https://arstechnica.com/?p=1846055">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>My wife just completed a 40 week body building program this morning</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
It’s a girl and weighs 7lbs 12 oz.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/BrokenChimera420"> /u/BrokenChimera420 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/txdr8n/my_wife_just_completed_a_40_week_body_building/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/txdr8n/my_wife_just_completed_a_40_week_body_building/">[comments]</a></span></p></li>
<li><strong>Man: “Waitress, can I ask you something about the menu please”</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Waitress: <em>slaps his face</em>
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“The men I please are none of your damn business!”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/maryssabelle1"> /u/maryssabelle1 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/txhfmm/man_waitress_can_i_ask_you_something_about_the/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/txhfmm/man_waitress_can_i_ask_you_something_about_the/">[comments]</a></span></p></li>
<li><strong>A guy starts working at a bakery</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He’s handed his rota and his eyes lighten up: “Great, it’s dinner-roll day!”. The supervisor is puzzled to see such enthusiasm for so mundane a task as baking dinner rolls, but sure enough, the new guy goes to it with zest and panache and is soon turning out dinner rolls the like of which the supervisor has never seen or tasted, imaginatively designed and with a taste and texture beyond all praise or even description.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
It’s the same again the next day when the new guy comes in and looks at the rota: “Wow, wholemeal loaf day!”. And sure enough, he puts the same verve and expertise into making wholemeal loaves as he did into dinner rolls the day before, and soon they are selling like something for which there ought to be a suitable simile when you’re telling a story about a bakery.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
On the Wednesday he takes one look at the words “Danish Pastry day” on the rota and immediately bursts into song, turning out tray after tray of beautifully formed and succulent Danish pastries, and on Thursday the excited shriek of “Doughnut day! Yes!!!” heralds an eight-hour shift of doughnuts that God Himself would forgive the sins of a whole world for.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
But on Friday: “I don’t understand it,” says the disappointed supervisor to the master baker. “It’s his cake day and he’s made barely any effort at all.”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/JustGlowing"> /u/JustGlowing </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/txf634/a_guy_starts_working_at_a_bakery/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/txf634/a_guy_starts_working_at_a_bakery/">[comments]</a></span></p></li>
<li><strong>My son was spending too much time playing computer games, so I said, “Son, when Abe Lincoln was your age, he was studying books by the light of the fireplace.”</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He considered this for a moment and replied: “When Abe Lincoln was your age he was The President of the United States.”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/FrostyDude78"> /u/FrostyDude78 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/tx223g/my_son_was_spending_too_much_time_playing/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/tx223g/my_son_was_spending_too_much_time_playing/">[comments]</a></span></p></li>
<li><strong>A man goes to confession</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Man: Forgive me farher for what I have sinned.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Father: What did you do my child?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Man: I went to my sister in law’s home. Just when I was leaving, it started raining and I had to stay there. We slept together.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Father: Pray to god my son for he is merciful.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Man: The day after that, I went to see my mother in law. Just when I was leaving, it started raining and I had to stay there. We slept together.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Father: Pray to god my son for he is merciful.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Man: Yesterday, I went to see my brother in law. Just when I was leaving, it started raining and I had to stay there. We slept together.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Upon hearing that, Father looks out from the window and says:
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The weather looks cloudy. Get the fuck out before it starts raining.
</p>
</div>
<!--
SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/nikan69"> /u/nikan69 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/txfrcj/a_man_goes_to_confession/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/txfrcj/a_man_goes_to_confession/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

File diff suppressed because one or more lines are too long